Key Takeaways
Bispecific antibodies are moving beyond heavily pretreated populations into earlier relapsed disease, combination regimens, and, in some settings, treatment of newly diagnosed patients.
As bispecifics and CAR T cell therapies occupy overlapping treatment settings, therapeutic sequencing is becoming a more important clinical-development consideration.
Format-specific assembly, impurity profiles, purification, stability, and process robustness remain important manufacturing considerations even as bispecifics become more familiar clinically.
Subcutaneous presentation can reduce administration burden, but formulation, pharmacokinetic bridging, step-up dosing, monitoring, and medication-error controls remain central to product design.
Wider use will depend partly on whether oncology practices can build the staffing, escalation pathways, monitoring capabilities, and coordination needed to deliver bispecific therapy safely outside specialized centers.
From Salvage Therapy to Treatment-Pathway Integration
Bispecific antibodies have established a substantial clinical presence in hematologic oncology, but their significance is increasingly defined by where they are being used rather than simply by the number of available products. Recent regulatory decisions and randomized trials show bispecifics moving from heavily pretreated populations into earlier relapsed disease, combination regimens, and, in some settings, treatment of newly diagnosed patients. That progression changes the development questions surrounding the modality. A therapy intended for patients with few remaining options occupies a different clinical and operational position from one that must fit into a longer, more complex treatment course.
Multiple myeloma provides one of the clearest recent examples. In March 2026, the U.S. Food and Drug Administration (FDA) approved teclistamab in combination with daratumumab and hyaluronidase for adults with relapsed or refractory multiple myeloma after at least one prior line containing a proteasome inhibitor and an immunomodulatory agent.1 The same regulatory action converted teclistamab monotherapy, indicated after at least four prior lines, from accelerated to traditional approval. The contrast places the evolution of the drug within a single regulatory frame: a bispecific initially associated with heavily pretreated disease has now entered combination use much earlier in the relapsed treatment course.
The shift rests on randomized phase III evidence. The MajesTEC-3 clinical trial enrolled patients who had received one to three previous lines of treatment and compared teclistamab plus daratumumab with established daratumumab-containing regimens. Progression-free survival (PFS) was significantly longer with the bispecific-containing regimen, with a reported hazard ratio of 0.17.2
A similar progression is visible in follicular lymphoma (FL). In November 2025, the FDA approved epcoritamab with lenalidomide and rituximab for relapsed or refractory FL and simultaneously converted the later-line epcoritamab monotherapy indication to traditional approval.3 EPCORE FL-1 enrolled patients after at least one previous systemic therapy and demonstrated superiority of the epcoritamab-containing regimen over lenalidomide and rituximab for response and PFS.4
Bispecific integration has advanced further in B cell acute lymphoblastic leukemia (ALL). Blinatumomab is approved as part of consolidation for newly diagnosed Philadelphia chromosome–negative B cell precursor ALL, following phase III evidence showing an overall-survival benefit when it was added to consolidation chemotherapy in adults who had already achieved measurable residual disease-negative remission. In this setting, the bispecific is part of the therapeutic sequence for newly diagnosed disease rather than an option reserved for repeated treatment failure.5
These examples do not mean that every heme-onc bispecific is advancing earlier at the same pace. They do show that the modality can no longer be characterized solely by its role in highly refractory disease. Broader use brings bispecifics into treatment settings with more alternatives, longer sequences, and more opportunities for product characteristics to affect how readily a therapy can be incorporated into care.
Earlier Use Makes Sequencing a Central Clinical Question
As bispecific antibodies and chimeric antigen receptor (CAR)-T cell therapies occupy overlapping portions of the treatment landscape, particularly in multiple myeloma and aggressive B cell lymphomas, the question becomes when one T cell–redirecting approach should be used relative to another.
The pace of change is reflected in the use of a living guideline for multiple myeloma. Updated ASCO recommendations incorporate emerging evidence for T cell–redirecting therapies within the relapsed or refractory setting and recognize that treatment selection must account for disease characteristics, previous therapy, patient factors, convenience, access, and other practical considerations. The recurrent update process allows the recommendations to respond as new evidence changes the relative position of available options.6
The myeloma literature likewise identifies patient selection and sequencing between CAR-T cells and bispecific antibodies as an active clinical problem rather than a settled hierarchy.7 Diffuse large B cell lymphoma adds another layer of complexity. Relapse timing, individual patient characteristics, CAR-T eligibility, and access to cellular therapy can all influence the sequence in which newer treatments are considered.8
Clinical outcomes following CAR-T cell therapy suggest that treatment history may matter biologically as well as logistically. In a real-world analysis of 92 patients with relapsed or refractory large B cell lymphoma who received a bispecific antibody after CAR-T failure, the overall response rate was 43%. Outcomes differed according to how quickly disease returned after CAR T, with poorer responses and PFS among patients who relapsed within three months compared with those whose relapse occurred later.9
These findings do not establish a universal rule for whether bispecific therapy should precede or follow CAR-T. They make broad labels such as “relapsed or refractory” less informative as the treatment histories of trial participants become more complex. Prior antigen-directed and cellular therapies, the timing of progression, and the characteristics of intervening treatments can become important parts of the clinical context in which a bispecific is evaluated.
That has implications for development strategy. A therapy used after four or more prior regimens occupies a relatively constrained position. Once the same modality becomes available after one prior line, developers encounter a much wider range of potential predecessors and successors. Patient stratification, trial design, and clinical positioning increasingly have to account for that therapeutic history.
Combination Use Changes the Development Context
Movement earlier in treatment is occurring alongside another shift: bispecifics are increasingly entering combination strategies rather than functioning only as stand-alone rescue therapies.
The MajesTEC-3 trial paired teclistamab with daratumumab, while EPCORE FL-1 added epcoritamab to lenalidomide and rituximab. Both were randomized phase III programs conducted in populations with substantially less prior treatment than those associated with the original late-line bispecific paradigm. Blinatumomab provides a related example from newly diagnosed disease, where it is incorporated into consolidation rather than deployed only after established therapy has failed.2,4,5
A bispecific used within a multidrug regimen must fit alongside other schedules, routes of administration, toxicity profiles, and monitoring requirements. Dosing frequency, treatment duration, and administration burden can therefore influence how readily the regimen can be incorporated into practice.
As bispecifics become components of broader therapeutic strategies, developers must consider how the product functions within the surrounding regimen as well as how the molecule performs on its own.
Clinical Familiarity Does Not Eliminate Manufacturing Complexity
Greater clinical familiarity with bispecific antibodies does not make them conventional monoclonal antibodies (mAbs) from a manufacturing perspective. Their production can draw heavily on established antibody-manufacturing experience, but molecular architecture and physicochemical behavior introduce challenges that differ among bispecific formats.
Many downstream strategies retain familiar separation mechanisms based on affinity, charge, size, hydrophobicity, and mixed-mode interactions. The difference lies in what those processes may need to separate. Bispecific assembly can generate mispaired molecules, undesired fragments, aggregates, and other unwanted species that require control strategies suited to the particular architecture.10
The manufacturing problem begins before purification. Bispecific production encompasses antibody engineering, expression-system selection, upstream process optimization, stability, and developability, with structural complexity influencing how efficiently the intended molecule can be expressed and assembled.11
Downstream development must then remove product- and process-related impurities without sacrificing acceptable yield and productivity. Purification strategy consequently involves a balance among purity, process performance, and recovery rather than a single objective of maximizing clearance of unwanted species.12
The diversity of architectures argues against treating bispecific manufacturing as a single standardized problem. Some platforms can leverage substantial portions of established mAb processes, while others require additional engineering or separation strategies to control format-specific species. Wider clinical use makes unresolved manufacturability issues more consequential later in development, when process robustness, reproducibility, and dependable supply assume greater importance.
Current evidence supports greater emphasis on manufacturing robustness and scalable process performance rather than a conclusion that bispecific growth has already created a broad capacity shortage. Commercial expansion increases the value of resolving format-specific manufacturing challenges early enough to avoid dependence on less robust or inefficient processes as demand grows.
Formulation and Presentation Become Part of Clinical Positioning
Subcutaneous (SC) delivery is already an established feature of the commercial heme-onc bispecific landscape. Teclistamab, for example, is administered subcutaneously and uses a defined step-up regimen intended to reduce the risk of cytokine release syndrome (CRS). Its route of administration, dosing architecture, and early monitoring requirements are integral to how the product is used rather than incidental features of its presentation.13
Mosunetuzumab provides a particularly instructive case because the same therapeutic molecule now exists in intravenous (IV) and SC forms. FDA-approved Lunsumio Velo is administered subcutaneously, while the original Lunsumio presentation is administered intravenously. FDA labeling specifically distinguishes the dosing and administration instructions for the two formulations and warns against substituting one for the other.14
The SC product also requires distinct commercial presentations. Lunsumio Velo is supplied as 5 mg/0.5 mL and 45 mg/mL single-dose vials and uses its own defined step-up schedule.
Development of the SC formulation involved more than selecting a different injection route. The pivotal program evaluated whether SC administration could provide exposure comparable with IV treatment and demonstrated noninferiority for the specified pharmacokinetic (PK) measures, while efficacy was consistent with the IV experience. The SC cohort also had a numerically lower incidence and severity of CRS than the within-study IV comparator, and the study identified shorter administration time and outpatient accessibility among the practical advantages of the SC presentation.15
The case demonstrates why route of administration can become a development strategy rather than a late packaging decision. A new presentation may require changes in formulation concentration, dose volume, commercial configuration, PK bridging, dosing instructions, and safeguards against medication errors. Those decisions connect formulation science and manufacturing directly with clinical and regulatory development.
For bispecifics entering competitive treatment settings, such attributes can contribute to clinical positioning. An efficacious molecule still has to be delivered in a way that fits the intended regimen and site of care.
Step-Up Dosing Creates an Operational Footprint Around the Product
A simpler route of administration does not necessarily produce a simple treatment model. Several T cell–engaging bispecifics rely on step-up dosing to mitigate early immune-mediated toxicities, particularly CRS. Teclistamab and SC mosunetuzumab both use structured step-up schedules, with accompanying monitoring and toxicity-management requirements.
Those requirements extend well beyond the injection itself. Outpatient implementation models emphasize multidisciplinary staffing, patient-selection criteria, step-up procedures, adverse-event recognition and management, capacity planning, escalation pathways, and education for patients and caregivers.16
This distinction matters when evaluating improvements in formulation or administration time. An SC injection may reduce chair time relative to an infusion, but total treatment burden also includes observation, toxicity preparedness, communication among care teams, and the ability to escalate rapidly when complications occur.
The intended care setting therefore becomes relevant during development. A dosing schedule that can be managed efficiently at a major academic center may place different demands on a smaller oncology practice. Product presentation and treatment protocol together help determine what infrastructure must surround the therapy.
Moving From Academic Centers to the Community
Efforts to transfer bispecific care beyond specialized academic hospitals are beginning to define what safe decentralization requires. The issue is no longer simply whether outpatient or community delivery is possible, but whether the receiving site has the clinical systems needed to manage treatment reliably.
A 2026 European consensus involving 53 clinicians across six countries addressed both outpatient step-up dosing and transfer of patients receiving B cell maturation antigen (BCMA)-directed bispecific antibodies from academic hospitals to community centers. Recommendations included trained personnel, urgent laboratory access, on-site medications for toxicity management, around-the-clock escalation pathways, appropriate patient selection, caregiver support, and infection-management procedures.17
Experience from an independent U.S. community oncology practice provides a complementary example. The practice implemented outpatient BCMA bispecific step-up dosing in response to limitations associated with hospital-based initiation, including resource utilization, inconvenience for patients, and constraints on access.18
These models make clear that decentralization involves transfer of capability, not simply transfer of drug administration. Community centers need defined responsibilities, appropriate expertise, access to urgent evaluation, and clear pathways for escalation or transfer when complications exceed local capacity.
Wider clinical eligibility will not necessarily translate into wider use if treatment remains concentrated in a limited number of specialized centers. Developing reliable models for transferring care can therefore influence how broadly bispecific therapy can be delivered outside the institutions where much of the early experience accumulated.
Access Becomes Part of the Mainstreaming Test
Broader regulatory eligibility does not automatically translate into practical access. Barriers to bispecific therapy in multiple myeloma include geographic, socioeconomic, patient-level, health-system, and financial factors, demonstrating that access extends beyond whether a therapy has received regulatory approval.19
Site of care is one component. Patients who must travel to specialized centers for treatment initiation or monitoring may face geographic and logistical burdens even when they meet the clinical criteria for therapy. Health systems, meanwhile, must provide trained personnel, appropriate monitoring, and pathways for managing serious adverse events.
Community delivery can address some of these constraints, but only where local practices can build the necessary clinical infrastructure. The community step-up experience and the European recommendations both show that extending bispecific treatment beyond academic centers requires preparation, staffing, protocols, and coordination rather than a simple change in location.
The distinction between clinical availability and usable access may become more important as bispecifics reach patients earlier in treatment. An indication may define who is eligible, but the surrounding care model helps determine who can realistically receive the therapy.
Designing Bispecifics for Routine Use
Bispecific antibodies are entering a different stage of development in hematologic oncology. Randomized phase III trials have established bispecific-containing combinations in earlier relapsed multiple myeloma and FL, while blinatumomab has demonstrated that T cell–engaging bispecific therapy can become part of treatment for newly diagnosed disease.
That expansion broadens the definition of a successful product. Clinical activity remains fundamental, but therapeutic sequencing matters more when CAR-T cells and other immune-directed approaches occupy adjacent positions in the treatment course. Manufacturing robustness becomes more consequential as use extends beyond limited late-line populations. Formulation and presentation can influence administration burden and site-of-care options, while delivery requirements can determine whether clinically eligible patients can realistically access treatment.
For bispecific antibodies, the transition toward routine use therefore extends beyond efficacy. Products intended for broader adoption will have to be manufactured consistently, incorporated logically into evolving treatment strategies, presented in forms that support practical administration, and delivered through care models capable of making their clinical potential broadly usable.
References
1. “FDA approves teclistamab in combination with daratumumab hyaluronidase-fihj for relapsed or refractory multiple myeloma.” U.S. Food and Drug Administration. 5 Mar. 2026.
2. Costa, Luciano J, et al. “Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma.” New England Journal of Medicine. 394: 739–752 (2026).
3. “FDA approves epcoritamab-bysp for follicular lymphoma indications.” U.S. Food and Drug Administration. 18 Nov. 2025.
4. Falchi, Lorenzo, et al. “Epcoritamab, lenalidomide, and rituximab versus lenalidomide and rituximab for relapsed or refractory follicular lymphoma (EPCORE FL-1): a global, open-label, randomised, phase 3 trial.” The Lancet. 407: 161–173 (2026).
5. “FDA approves blinatumomab as consolidation for CD19-positive Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia.” U.S. Food and Drug Administration. 14 Jun. 2024.
6. Banerjee, Rahul, et al. “Treatment of Multiple Myeloma: ASCO Living Guideline, Version 2026.1.1.” Journal of Clinical Oncology. 44: e113–e124 (2026).
7. Puppi, Michele, et al. “Bispecific Antibodies and CAR T in Multiple Myeloma: Appropriate Selection of Patients and Sequencing.” Mediterranean Journal of Hematology and Infectious Diseases. 1 May 2025.
8. Wang, Jacqueline F, Gilles Salles, and Efrat Luttwak. “SOHO State of the Art Updates and Next Questions | Sequencing Therapies in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Evidence, Challenges, and Opportunities for Cure.” Clinical Lymphoma, Myeloma & Leukemia. 26: 273–284 (2026).
9. Shumilov, Evgenii, et al. “Outcomes of bispecific antibody therapy after CAR T-cell failure in relapsed/refractory large B-cell lymphoma.” Blood Advances. 9: 3955–3966 (2025).
10. Chen, Serene W, and Wei Zhang. “Current trends and challenges in the downstream purification of bispecific antibodies.” Antibody Therapeutics. 4: 73–88 (2021).
11. Karbyshev, Mikhail S, et al. “Trends and challenges in bispecific antibody production.” Journal of Chromatography A. 15 Mar. 2025.
12. Li, Qian, et al. “The downstream purification of bispecific antibodies.” Analytical Biochemistry. Jan. 2025.
13. “TECVAYLI (teclistamab-cqyv) injection, for subcutaneous use: Prescribing Information.” U.S. Food and Drug Administration. Revised Mar. 2026.
14. “LUNSUMIO VELO (mosunetuzumab-axgb) injection, for subcutaneous use: Prescribing Information.” U.S. Food and Drug Administration. Revised Dec. 2025.
15. Bartlett, Nancy L, et al. “Fixed-Duration Subcutaneous Mosunetuzumab in Relapsed/Refractory Follicular Lymphoma: Pivotal Phase 2 Primary Analysis.” American Journal of Hematology. 101: 986–997 (2026).
16. Garfall, Alfred L, et al. “A roadmap to implementing outpatient administration of bispecific antibodies in multiple myeloma.” Frontiers in Oncology. 30 Jul. 2025.
17. Mateos, María-Victoria, et al. “European Recommendations for Transitioning the Care of Patients With Multiple Myeloma Treated With B-Cell Maturation Antigen Bispecific Antibodies From Academic Hospitals to Community-Based Centers and for Outpatient Step-Up Dosing.” eJHaem. 14 May 2026.
18. Resnick, Yonatan, Patrick Boland, and John P Winters. “Implementation of a Model Program at an Independent Community Oncology Practice for the Outpatient Administration of B-Cell Maturation Antigen–Directed Bispecific Antibody Step-Up Doses.” JCO Oncology Practice. 23 Apr. 2026.
19. Ekpenyong, Emmanuel, et al. “Access to Bispecific Therapies for Multiple Myeloma: An Overview of Barriers and Emerging Solutions.” Clinical Lymphoma, Myeloma & Leukemia. 26: e885–e892 (2026).
